Phathom Pharmaceuticals Inc

-0.32 (-1.08%)
Products, Earnings Announcements

Phathom Announces Results From Phase 1 Study Testing Gastric Acid Inhibition Of Vonoprazan And Lansoprazole

Published: 09/27/2021 12:27 GMT
Phathom Pharmaceuticals Inc (PHAT) - Phathom Pharmaceuticals Announces Results From Vono-103, a Phase 1 Study Evaluating Gastric Acid Inhibition of Vonoprazan and Lansoprazole (prevacid®).
Phathom Pharmaceuticals - Vonoprazan 20 Mg Demonstrated Significantly Greater Acid Suppressive Effects Over 7-day Study Period Versus Lansoprazole 30 Mg.
Phathom Pharmaceuticals Inc - in Study, Vonoprazan Demonstrated Significantly Greater Acid Inhibition As Compared to Lansoprazole.
Phathom Pharmaceuticals Inc - Study Treatments Were Generally Well Tolerated With No Serious Adverse Events Reported.
Revenue is expected to be $0 Million
Adjusted EPS is expected to be -$0.99

Next Quarter Revenue Guidance is expected to be $0 Million
Next Quarter EPS Guidance is expected to be -$1.10

More details on our Analysts Page.